[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"content-doc-dcio2f8de028":3},{"user":4,"document":8,"mainDocument":27,"columnUrl":29,"subscription":30,"footer":42,"text":80},{"isAuthenticated":5,"isAdmin":5,"displayName":6,"avatarUrl":6,"nid":6,"groupLevel":7},false,"",-10,{"id":9,"fullTitle":10,"subTitle":6,"url":11,"columnId":12,"columnName":13,"columnUrl":14,"summary":6,"contentHtml":15,"mainContentHtml":6,"posterUrl":16,"createDate":17,"displayDate":18,"displayDateSlash":19,"pageviews":20,"tags":21,"hidden":5,"isSubContent":5,"replyDocOrTargetId":6,"contentType":23,"videoId":6,"liveVideoUrl":6,"useContentVideo":5,"duration":24,"price":24,"priceText":25,"priceBadgeText":25,"priceBadgeClass":26,"freeForMinGroupLevel":24,"redirectUrl":6,"readyToStream":5},"dcio2f8de028","一周两度受挫！诺华(NVS)心脏病重磅药III期折戟，股价大跌安进(AMGN)“躺枪”","\u002Fdoc\u002Fdcio2f8de028","col18178739ee","美股资讯","\u002Fcol\u002Fcol18178739ee","\u003Cp>\n\u003C\u002Fp>\u003Cp>\u003Cspan>美股投资网获悉，瑞士制药巨头诺华制药(NVS)再遭临床试验打击——一周之内，该公司第二项重磅候选药物在后期研究中折戟。此次失利的是其潜在明星心脏病药物pelacarsen。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>据了解，该药物确实降低了脂蛋白(a)水平——这是一种主要由遗传因素决定的心血管疾病风险指标，约五分之一的人群受其影响。然而，诺华于上周五晚些时候表示，尽管脂蛋白(a)水平有所下降，但与安慰剂组相比，该药并未显著减少心血管死亡、心脏病发作或中风事件。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>这一失败沉重打击了业界对该药物开辟心血管疾病预防新路径的期望。而就在几天前，诺华刚刚因三名患者死亡，暂时叫停了一项针对自身免疫性疾病的实验性细胞疗法试验。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>受此消息影响，诺华在美上市股票上周五常规交易结束后一度下跌逾7%。开发类似心脏药物的安进(AMGN)股价上周五盘后也下挫近6%。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>杰富瑞分析师Michael Leuchten指出“这一结果令市场质疑，任何降低脂蛋白(a)的疗法究竟能否最终带来心血管方面的临床获益。”不过他也表示，市场的负面反应可能有所夸大，因为即便该试验取得成功，也仍会引发关于哪些患者能真正受益、以及该药如何与竞品抗衡等疑问。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>诺华正寄望于一系列新药来支撑增长，以应对旗下多款重磅产品专利即将到期的压力。首席执行官Vas Narasimhan曾表示，若后期试验结果理想，公司有望上调2030年前年销售额增长5%至6%的预期。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>诺华下一个备受关注的研发节点，是一款旨在从基因层面治疗DM1(一种肌肉萎缩疾病)的实验性注射药物，而非仅缓解症状。该疗法名为del-desiran，也是诺华以120亿美元收购Avidity的核心资产。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>这两次失利的意义不仅限于单一药物。诺华此前将pelacarsen和rapcabtagene autoleucel(简称rap-cel)双双定位为各自领域重塑治疗格局的潜在突破口——前者瞄准以往无法干预的遗传性心血管风险，后者则将CAR-T细胞疗法拓展至自身免疫疾病领域。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>值得注意的是，pelacarsen的失利发生在上周诺华喜忧参半的背景下彼时，该公司另一项实验性疗法确实兑现了承诺，带来一丝慰藉。其多发性硬化症口服药remibrutinib在两项后期试验中取得成功，推动公司股价周二上涨逾6%。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>诺华目前尚未公布pelacarsen试验失败的详细数据，包括该药距离达到主要终点有多接近，以及是否存在某些亚组患者获益更多等情况。该公司表示，完整结果将在即将召开的医学会议上予以披露。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>最专业的美股资讯,推荐美股大数据 \u003Ca href=\"https:\u002F\u002FStockwe.com\u002F\">https:\u002F\u002FStockwe.com\u002F\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>如何识别美股市场异常波动？美国机构主力资金买卖情况，出货和吸筹，使用美股投资网VIP会员，2008年成立于美国硅谷，由前纽约证券交易所分析师Ken创立，联合多位摩根斯坦利分析师，谷歌 Meta工程师利用AI和大数据，配合十多年美股实战经验和业内量化模型，建立了一个股市数据库 \u003Ca href=\"https:\u002F\u002FStockWe.com\u002F\">https:\u002F\u002FStockWe.com\u002F\u003C\u002Fa> 每天处理千万级股票数据：捕捉期权大单，实时主力资金流向、机构持仓变化、川普突发新闻，精准交易信号第一时间发到您手机APP！\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003C\u002Fp>","https:\u002F\u002Fwww.tradesmax.com\u002Fimages\u002Fa_Stock\u002FM\u002FMG\u002FMG.jpg","2026-09-08T17:10:01","2026.09.08","2026\u002F09\u002F08",30475,[22],"MG","Article",0,"免费","success",{"id":9,"fullTitle":10,"subTitle":6,"url":11,"columnId":12,"columnName":13,"columnUrl":14,"summary":6,"contentHtml":15,"mainContentHtml":6,"posterUrl":16,"createDate":17,"displayDate":18,"displayDateSlash":19,"pageviews":20,"tags":28,"hidden":5,"isSubContent":5,"replyDocOrTargetId":6,"contentType":23,"videoId":6,"liveVideoUrl":6,"useContentVideo":5,"duration":24,"price":24,"priceText":25,"priceBadgeText":25,"priceBadgeClass":26,"freeForMinGroupLevel":24,"redirectUrl":6,"readyToStream":5},[22],"\u002Fcol\u002Fstocknews",{"visible":5,"marketingHtml":31,"services":32,"recentDocuments":41},"\u003Cfigure class=\"image\">\u003Ca href=\"https:\u002F\u002Fstockwe.com\u002Fdoc\u002Fdcio537efad5\" rel=\"noopener noreferrer\">\u003Cimg src=\"\u002Fimg\u002Fstockwewebfiles\u002Fweb-202408-stk\u002F1586109431mceclip0.jpg\">\u003C\u002Fa>\u003C\u002Ffigure>\u003Cdiv class=\"text-center\">\u003Ch2 class=\"card-title mx-auto\">\u003Cbr>\u003Ca rel=\"noopener noreferrer\" href=\"https:\u002F\u002Fstockwe.com\u002Fdoc\u002Fdcio537efad5\">案例介绍：英伟达深度研究报告\u003C\u002Fa>\u003C\u002Fh2>\u003C\u002Fdiv>",[33,37],{"productId":34,"serviceName":35,"priceText":36},"prod_PPxdDdK87QaiLv","月付","$12.95美元",{"productId":38,"serviceName":39,"priceText":40},"prod_PPxeMs3bix1da5","年付","$149.00美元",[],{"links":43,"images":71,"summaryHtml":76,"aboutTitle":77,"aboutHtml":78,"copyrightHtml":79},[44,47,50,53,56,59,62,65,68],{"label":45,"url":46},"深度报告","\u002Fcol\u002FdepthReport",{"label":48,"url":49},"VIP会员","\u002Fvip",{"label":51,"url":52},"期权推荐","\u002FOption",{"label":54,"url":55},"低价暴涨股","\u002FPenny",{"label":57,"url":58},"AI智能体","\u002FAiAgent",{"label":60,"url":61},"常见问题","https:\u002F\u002Fstockwe.com\u002FFAQ",{"label":63,"url":64},"美股课程","\u002Fcol\u002Fvideos",{"label":66,"url":67},"免责声明","\u002Fdisclaimer",{"label":69,"url":70},"联系我们","\u002FContactUs",[72,73,74,75],"\u002Fimg\u002Fstockwebsiteblob\u002Fweb-202509-stk\u002FUploaderzic2tuwsol2_2025_09_11_18_21_07.gif","\u002Fimg\u002Fstockwebsiteblob\u002Fweb-202509-stk\u002FUploadercakzdvydksw_2025_09_03_09_00_56.png","\u002Fimg\u002Fstockwebsiteblob\u002Fweb-202509-stk\u002FUploadergtjyagwvoyk_2025_09_14_08_32_05.png","\u002Fimg\u002Fstockwebsiteblob\u002Fweb-202509-stk\u002FUploader3u0tt4jhlqh_2025_09_23_22_30_48.png","邮箱: buy@TradesMax.com 美国电话 626-378-3637","公司介绍","\u003Cp class=\"MsoNormal\">美股大数据 \u003Ca href=\"https:\u002F\u002Fstockwe.com\" rel=\"noopener\">StockWe.com\u003C\u002Fa> 是一个美国领先的金融和美股信息大数据提供商，紧盯华尔街金融市场和行情，2008年成立于美国硅谷，创始人是前纽约证券交易所资深分析师Ken，联合多位摩根斯坦利分析师，谷歌 Meta工程师利用AI和大数据，配合十多年美股实战经验和业内量化交易模型，每天处理海量股票数据：挖掘潜力大牛股，捕捉期权异动大单，实时主力资金流向、机构持仓变化、川普突发新闻，美股买卖信号第一时间发到您手机APP。\u003C\u002Fp>","专业美股投资者都在这里",{"loading":81,"search":82,"searchPlaceholder":82,"hotContent":83,"draft":84,"noData":85,"searchNoData":86,"courseContent":87,"more":88,"buyNow":89,"subscribeNow":90,"encoding":91,"paidContent":92},"Loading...","搜索","热门内容","草稿","目前没有任何内容公布","当前检索内容没有数据","课程内容","更多","立即购买后观看","- 立即订阅 -","视频编码中...","付费内容"]